Dental Management of Asthmatic Patients

01

Pathophysiology and Bronchial Inflammation

Definition and Algerian context

Bronchial asthma is a chronic inflammatory disease of the airways characterized by bronchial hyperreactivity and variable airflow obstruction. In Algeria, it is the most prevalent chronic disease in children, with an estimated prevalence of 8.7%, highlighting the importance of standardizing dental care for this population.

This heterogeneous disease rests on an inflammatory cascade involving mast cells, eosinophils, T lymphocytes and epithelial cells — leading to bronchial remodeling that amplifies hyperreactivity to external stimuli.

Triggering stimuli in the dental office

Irritants to control without exception

Resin dust during polishing or grinding procedures
Rinse sprays or topical anesthetic aerosols
Strong odors from chemical products (eugenol, solvents, resins)
Stress and anxiety — the primary trigger in the dental office
Strict supine position (diaphragmatic compression)

FeNO — Marker of active inflammation

Fractional exhaled nitric oxide

NO produced in excess via NOSII activation by inflammatory cytokines
Elevated FeNO = active subclinical inflammation
Heightened perioperative exacerbation risk even in asymptomatic patients
Absence of declared symptoms does not guarantee absence of bronchial inflammation

02

GINA Classification — Control and Operative Risk

Risk stratification according to level of control

Control level	Clinical features (4 weeks)	Implications for the clinician
Well controlled	Daytime symptoms ≤ 2/week · No nocturnal awakening · Reliever use ≤ 2/week	Routine care permitted — standard stress management precautions
Partly controlled	Daytime symptoms > 2/week · Nocturnal awakening · Activity limitation	Identify triggers · Light sedation feasible · Verify treatment adherence
Uncontrolled	≥ 3 partly-controlled criteria · Frequent exacerbations	Defer elective care · Pulmonologist consultation · Emergencies in a secure setting

Severe asthma — Definition and criteria Disease remaining uncontrolled despite high-dose ICS + LABA, or requiring chronic oral corticosteroids. Respiratory function may be permanently impaired with FEV1 < 80% of predicted value. These patients require close coordination with a pulmonologist before any elective procedure.

Pre-appointment assessment — Five essential questions

Has the patient had exacerbations or emergency visits in the past 4 weeks?
Has the patient used their rescue bronchodilator more than twice per week?
Is the patient carrying their rescue inhaler (salbutamol) today?
Does the patient have a known sulfite allergy or nasal polyposis?
Is the patient on long-term oral corticosteroids (adrenal insufficiency risk)?

03

Effects of Inhaled Medications on the Oral Cavity

Common mechanism — Oropharyngeal particle deposition

Asthma medications exert direct and indirect deleterious effects on both hard and soft oral tissues. These effects primarily result from the inhalation route of delivery, which promotes significant deposition of active substances in the oropharynx at the expense of the desired pulmonary distribution.

Adverse effects by therapeutic class

1

β2-agonists — Hyposalivation and caries

Salbutamol and fenoterol reduce total salivary flow by 26% and parotid saliva by approximately 36%.

Dry powder inhalers contain lactose monohydrate as an excipient — a fermentable substrate for S. mutans and Lactobacilli.

2

pH drop — Enamel erosion

Frequent inhalation causes salivary pH to fall below the critical threshold of 5.5 for up to 30 minutes after each dose.

This repeated acidity promotes enamel erosion and irreversible demineralization of dental hard tissues.

3

Inhaled corticosteroids — Oral candidiasis

Fluticasone and budesonide induce local immune suppression of the oral mucosa, promoting opportunistic proliferation of Candida albicans.

Risk is markedly higher without post-inhalation mouth rinsing or without a spacer device.

4

Anticholinergics — Intense xerostomia

Ipratropium bromide inhibits parasympathetic stimulation of salivary glands, inducing severe dry mouth.

Combination inhalers (ICS + long-acting β2) combine reduced salivary flow with local immune suppression — cumulative risk.

Ciclesonide (Alvesco) — A prodrug with lower local risk Certain newer treatments such as ciclesonide are prodrugs activated only in the lungs, potentially reducing the incidence of oral candidiasis by limiting local steroid activity in the oropharynx.

04

Chairside Operative Protocols

Organization

Appointment planning and setup

Maximum stress reduction is the fundamental prerequisite — the primary trigger of bronchospasm in the dental office

Timing and duration

Prefer morning appointments — respiratory function is statistically more stable. Limit session length to avoid physical and nervous exhaustion.

Patient positioning

Strict supine position may aggravate dyspnea through diaphragmatic compression. A semi-reclined position is preferred to facilitate chest expansion.

Pre-treatment check

Always confirm the patient has their rescue inhaler (salbutamol) at the appointment. Never begin treatment without this verification.

!

Nitrous oxide (N₂O/O₂) — Conscious sedation in asthmatic patients

Advantages of N₂O/O₂

Anxiolytic and analgesic properties without bronchial irritation. The high oxygen concentration (50%) is inherently beneficial for the asthmatic patient. Preferred option for the anxious but well-controlled asthmatic.

Specific contraindications

Avoid during an acute episode or severe nasal obstruction (nasal breathing via the mask is essential). Deep sedation is contraindicated outside a hospital setting in very severe asthma — risk of respiratory depression.

05

Local Anesthesia and Vasoconstrictors

The sulfite debate — A rigorous assessment of actual risk

Anesthetic solutions containing vasoconstrictors require the addition of sodium metabisulfite as a preservative. In approximately 4% of severely corticosteroid-dependent asthmatics, sulfites can trigger an acute bronchospasm through a hypersensitivity reaction.

However, scientific literature shows that for 96% of asthmatics, the risk is extremely low. A standard restaurant meal can contain up to 200 mg of sulfites — approximately 27 times the dose present in a lidocaine with epinephrine cartridge.

Recommendations by patient profile

Patient profile	Anesthetic choice	Rationale
Well-controlled asthma	Lidocaine with epinephrine	Vasoconstrictors are not contraindicated — deeper, longer-lasting anesthesia
Partly controlled asthma	Articaine or Lidocaine — with precautions	Slow fractional injection · Enhanced monitoring · Patient must have inhaler
Severe unstable asthma or known sulfite allergy	Mepivacaine 3% without vasoconstrictor	Eliminate any sulfite risk — action duration is sufficient
Samter's Triad (AERD)	Mepivacaine 3% — avoid epinephrine	Confirmed hypersensitivity background — maximum safety required

Injection technique — Non-negotiable rules Injection must always be performed slowly (1 ml per minute), fractionally, with systematic aspiration before injection. Monitor for any immediate adverse reaction. Articaine is often preferred for its excellent tissue diffusion; mepivacaine is the reference alternative without vasoconstrictor.

06

Samter's Triad — NSAIDs and Analgesic Prescribing

AERD (Aspirin-Exacerbated Respiratory Disease) — Potentially fatal reactions Samter's Triad combines asthma, nasal polyposis and severe intolerance to aspirin and COX-1-inhibiting NSAIDs. NSAID ingestion blocks the cyclooxygenase pathway, shunting arachidonic acid metabolism toward massive overproduction of bronchoconstricting leukotrienes. Reactions may require emergency hospitalization.

!

Identifying Samter's Triad in the dental history — Warning signals

Risk factors to screen for

History of respiratory reaction (dyspnea, wheezing, profuse rhinorrhea, urticaria) after taking aspirin, ibuprofen or naproxen. Documented nasal polyposis. Chronic severe asthma requiring long-term oral corticosteroids.

Clinical approach

If one or more criteria are present: prescribe paracetamol exclusively. Inform the patient of the risk. Document in the patient file. Refer to an allergist or pulmonologist for full evaluation.

Analgesic prescribing recommendations — Reference table

Drug	Risk	Recommendation
Aspirin	Severe bronchospasm (Samter's Triad)	Contraindicated if history of respiratory reaction
NSAIDs (Ibuprofen, Naproxen)	Asthma exacerbation via leukotriene shunting	Avoid — replace with paracetamol
Paracetamol (Acetaminophen)	Very low risk	First-line analgesic — well tolerated even in AERD
Opioids (Morphine, Codeine)	Histamine release · Respiratory depression	Extreme caution — use only with medical advice

07

Emergency Protocol — Bronchospasm in the Dental Office

Recognition of severity signs

Difficulty speaking or counting to 10 in a single breath
Agitation, diaphoresis, cyanosis of the lips or fingernails
Accessory respiratory muscle use — intercostal or supraclavicular retraction
Respiratory rate exceeding 25–30 cycles per minute
SpO2 < 92% on pulse oximeter reading
Peak expiratory flow (PEF) < 50% of predicted value

Immediate management algorithm for acute bronchospasm

Life-threatening emergency — every second counts. Memorize this sequence and display it in the dental office.

Step 1 — Immediate cessation of treatment

Remove all intraoral materials (rubber dam, instruments, cotton rolls)
Clear the airway and prevent any accidental aspiration

Step 2 — Patient positioning

Sit or semi-recline the patient to assist inspiratory effort
Never lay a patient in respiratory distress fully supine

Step 3 — Rapid-acting bronchodilator

Administer 2 to 4 puffs of salbutamol (Ventolin) via metered-dose inhaler
Use a spacer device to optimize pulmonary delivery of the drug
Repeat every 20 minutes if needed (maximum 3 rounds)

Step 4 — Oxygen therapy

Administer O2 at 6–10 L/min via face mask
Target: maintain SpO2 above 94%

Step 5 — Emergency services and adjunctive treatment

In Algeria: contact SAMU or Civil Protection if no immediate improvement
Refractory episode: methylprednisolone (Solu-Medrol) 20–40 mg IV/IM or terbutaline 0.5 mg SC
Associated anaphylaxis: epinephrine 0.3–0.5 mg IM into the thigh

08

Emergency Kit — Algeria

Regulatory composition — Recommendations from Algerian medical faculties (Constantine, Sétif)

Equipment / Drug	Indication	Route of administration
Salbutamol (Ventolin)	Rapid-acting bronchodilator	Inhalation — 2 to 4 puffs via spacer
Terbutaline (Bricanyl)	Severe acute asthma resistant to salbutamol	Subcutaneous injection — 0.5 mg
Epinephrine (Adrenaline)	Anaphylactic shock / Refractory asthma	Intramuscular injection — 0.3 to 0.5 mg
Methylprednisolone (Solu-Medrol)	Episode refractory to bronchodilators	IV or IM injection — 20 to 40 mg
Medical oxygen	Hypoxemia / Respiratory distress	Face mask — 6 to 15 L/min
Spacer device	Optimize bronchodilator pulmonary delivery	Interface between inhaler and patient
Pulse oximeter	SpO2 monitoring	Finger probe — alarm if SpO2 < 92%

Regulatory obligation — Algeria (MSPRH) Dental practitioners in Algeria are required to maintain a complete medical record for each patient, including a detailed asthma history and current treatment list. Any serious incident in the dental office must be reported to health authorities. Rigorous management of infectious healthcare waste (DASRI) is also a strict regulatory requirement.

09

Prevention and Patient Education

Post-inhalation hygiene

Protocol to teach every asthmatic patient

Mouth rinsing after inhalation is the single most effective preventive intervention — explain it at every appointment

Immediate rinsing

Systematic mouth rinse after every inhaler use with water, milk or 0.05% sodium fluoride solution. Neutralizes acidity and limits systemic corticosteroid absorption via the mucosa.

Delayed brushing

Do not brush immediately after inhalation — enamel is temporarily weakened by transient acidity. Wait 30 minutes before brushing.

Spacer device

Recommend a spacer device to reduce oropharyngeal deposition and improve pulmonary distribution of the inhaled medication.

Xerostomia management and remineralization

Individualized prophylactic strategy

Regular hydration with small sips of water throughout the day
Sugar-free chewing gum to stimulate endogenous saliva production
Professional application of fluoride varnish (especially in children)
Pit and fissure sealants on vulnerable surfaces in asthmatic children
High-concentration toothpaste (5000 ppm) if confirmed high caries risk

Algerian institutional framework

National School Oral Health Program

Regular dental screening of children in school settings
Special attention to asthmatic children during screening visits
Public health dental inspectors: oversight of guideline implementation
Combating childhood asthma: a school health priority (MSPRH)

10

Orthodontic Implications and Facial Growth

Chronic mouth breathing — Morphological consequences

Mouth breathing — a frequent consequence of nasal obstruction associated with asthma and allergic rhinitis — can have major morphological repercussions on facial skeletal development in children. The absence of physiological lingual pressure on the palate and the deviant breathing pattern are the primary mechanisms.

Dentofacial anomalies associated with persistent asthma — Increased prevalence

A

High-arched palate

High and narrow palatal vault due to the absence of physiological lingual pressure against the palate.

Deficient transverse development of the maxillary arch.

B

Long face (hyperdivergence)

Increased anterior facial height linked to chronic open mandibular posture.

Tendency toward skeletal hyperdivergence.

C

Increased overjet and anterior open bite

Significant overjet and increased risk of anterior open bite linked to low tongue posture and reduced lip muscle tone.

Increased traumatic risk to the maxillary incisors.

D

Dental crowding

Deficient transverse arch development leading to significant dental crowding.

Posterior crossbite is frequently observed.

Early orthodontic evaluation — Systematic recommendation For any child with persistent asthma, an orthodontic evaluation from age 6–7 years is recommended to anticipate and correct these growth anomalies through appropriate interceptive treatments (palatal expansion, swallowing rehabilitation, functional appliances).

11

Clinical FAQ

For 96% of asthmatics, vasoconstrictors are not contraindicated. Current guidelines confirm that lidocaine with epinephrine is permitted in well-controlled asthmatic patients. The restriction applies to two specific categories: patients with severe unstable asthma (risk of sulfite preservative reaction) and those with a documented sulfite allergy. In these cases, mepivacaine 3% without vasoconstrictor is the reference alternative. Always inject slowly (1 ml/min), fractionally, with systematic aspiration before injection.

Paracetamol (acetaminophen) is the first-line analgesic and should be systematically preferred. It is well tolerated even in patients with AERD (Samter's Triad). Ibuprofen and all NSAIDs should be avoided in asthmatic patients — particularly if the patient reports any history of respiratory drug reactions or has known nasal polyps — due to the risk of severe bronchospasm through leukotriene overproduction. Aspirin is formally contraindicated if AERD is suspected. Opioids (morphine, codeine) require extreme caution due to histamine release and the risk of respiratory depression.

Non-adherence is frequent and represents a major perioperative risk. Before starting treatment, assess control level using GINA criteria: a non-adherent patient is often partly or uncontrolled. For partly controlled asthma, urgent care can be performed with enhanced precautions (rescue inhaler verification, semi-reclined position, short session, elimination of triggers). For uncontrolled asthma: defer all elective care and refer to a pulmonologist for controller therapy optimization before any planned procedure. Document this clinical decision in the patient record.

Inhaled corticosteroids (fluticasone, budesonide) deposit in the oropharynx and produce local immune suppression of the oral mucosa, promoting opportunistic proliferation of Candida albicans. This risk is amplified by the absence of post-inhalation mouth rinsing and by inhaler use without a spacer (which increases oropharyngeal deposition). Prevention relies on systematic rinsing after every inhalation, use of a spacer device, and potentially transitioning to prodrugs such as ciclesonide that are activated only in the lungs. Established candidiasis is treated with topical amphotericin B or systemic fluconazole in coordination with the patient's pulmonologist.

Samter's Triad (AERD) is often unknown to the patient. Warning signals to screen for in the medical history: (1) History of respiratory reaction — dyspnea, wheezing, profuse rhinorrhea, urticaria — after aspirin, ibuprofen or naproxen; (2) Documented nasal polyposis or persistent nasal obstruction despite treatment; (3) Chronic severe asthma difficult to control requiring long-term oral corticosteroids. If one or more criteria are present: prohibit all NSAIDs, document in the patient record, and refer to an allergist or pulmonologist for confirmation and consideration of aspirin desensitization if indicated.

The five-step emergency algorithm: (1) Stop all treatment immediately and remove all intraoral materials; (2) Sit or semi-recline the patient — never lay them fully supine; (3) Administer 2 to 4 puffs of salbutamol (Ventolin) via spacer device if available; (4) Apply O2 at 6–10 L/min via mask to maintain SpO2 > 94%; (5) Call SAMU or Civil Protection if no improvement within 10–15 minutes. Refractory episode: Solu-Medrol 20–40 mg IV/IM. Associated anaphylaxis: epinephrine 0.3–0.5 mg IM. Always ensure the emergency kit is complete and the pulse oximeter is functional before every appointment.

Ref

References

Pathophysiology, epidemiology and GINA classification

1

Guideline GINA. Global Strategy for Asthma Management and Prevention — Pocket Guide. Global Initiative for Asthma. 2024.
ginasthma.org — GINA Pocket Guide 2024
2

Review Nitric oxide and asthma severity: towards a better understanding of asthma phenotypes. PMC / J Breath Res. 2024.
pmc.ncbi.nlm.nih.gov — FeNO and asthma phenotypes
3

Algeria Université de Tlemcen. Management of severe asthma in a pulmonology department. Dspace Tlemcen. 2023.
dspace.univ-tlemcen.dz — Severe asthma management in Algeria
4

Guideline Global Asthma Network. The Global Asthma Report 2022. GAN. 2022.
globalasthmanetwork.org — Global Asthma Report

Effects of inhaled medications on oral health

5

Systematic review Drugs prescribed for asthma and their adverse effects on dental health. PMC / Oral Health Prev Dent. 2023.
pmc.ncbi.nlm.nih.gov — Asthma drugs and dental health
6

Clinical study Impact of inhalation therapy on oral health. PMC / J Asthma. 2020.
pmc.ncbi.nlm.nih.gov — Impact of inhalation therapy on oral health
7

Pediatric study Dental management of pediatric patients with bronchial asthma. PMC / J Clin Pediatr Dent. 2022.
pmc.ncbi.nlm.nih.gov — Dental management of pediatric asthma patients

Local anesthesia, vasoconstrictors and conscious sedation

8

Narrative review Pharmacological interactions of epinephrine at concentrations used in dental anesthesiology: an updated narrative review. PMC / Anesth Prog. 2023.
pmc.ncbi.nlm.nih.gov — Epinephrine in dental anesthesiology
9

Guideline AAPD. Use of nitrous oxide for pediatric dental patients. American Academy of Pediatric Dentistry. 2023.
aapd.org — Nitrous oxide for pediatric dental patients
10

Guideline SaferCare Victoria. Sedation in children with respiratory distress including asthma. Good Practice Point. 2022.
safercare.vic.gov.au — Sedation in children with asthma

Samter's Triad (AERD) and analgesic prescribing

11

Guideline AAAAI. Aspirin-Exacerbated Respiratory Disease (AERD). American Academy of Allergy, Asthma & Immunology. 2024.
aaaai.org — AERD: definition and management
12

Review Aspirin-exacerbated respiratory disease: the dentist's role in recognition, referral, and management. SCIRP / Open Journal of Stomatology. 2021.
scirp.org — AERD and the dentist's role
13

PMC study Accidental ingestion of aspirin and NSAIDs is common in patients with AERD. PMC / J Allergy Clin Immunol Pract. 2022.
pmc.ncbi.nlm.nih.gov — NSAID ingestion in AERD patients

Dental office emergencies and emergency kit — Algerian context

14

Algeria Faculty of Medicine, University of Constantine 3. Emergency drugs and emergency kit in the dental office.
facmed.univ-constantine3.dz — Dental emergency kit
15

Algeria Faculty of Medicine, University of Constantine 3. Medical emergencies in the dental office.
facmed.univ-constantine3.dz — Medical emergencies in the dental office
16

Review Management of medical emergencies in the dental office: conditions in each country, the extent of treatment by the dentist. PMC / Int Dent J. 2021.
pmc.ncbi.nlm.nih.gov — Medical emergencies in the dental office

Facial growth and orthodontics

17

Pediatric study Dental management of pediatric patients with bronchial asthma — orthodontic implications. PMC. 2022.
pmc.ncbi.nlm.nih.gov — Orthodontic implications of asthma in children
18

Review Asthma and oral health — Links between asthma and dental health. Dental practice / PMC. 2023.
pmc.ncbi.nlm.nih.gov — Asthma and oral health links